Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/10801
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Готько, Євген Степанович | - |
dc.contributor.author | Tamas Pinter | - |
dc.contributor.author | Esteban Abella | - |
dc.contributor.author | Alvydas Cesas | - |
dc.contributor.author | Adina Croitoru | - |
dc.contributor.author | Jochen Decaestecker | - |
dc.contributor.author | Peter Gibbs | - |
dc.contributor.author | Jacek Jassem | - |
dc.contributor.author | Galina Petrova Kurteva | - |
dc.contributor.author | Jan Novotny | - |
dc.contributor.author | Seamus O'Reilly | - |
dc.contributor.author | Tomas Salek | - |
dc.contributor.author | May F. Mo | - |
dc.date.accessioned | 2016-11-28T09:29:34Z | - |
dc.date.available | 2016-11-28T09:29:34Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://dspace.uzhnu.edu.ua/jspui/handle/lib/10801 | - |
dc.description.abstract | Background: Theliteraturereportsthataddingbiologicstochemotherapy (ctx) mayincreasetheincidenceofclinicallysignificantneutropenia. histrialwasconductedtoevaluatetheefficacyof PEG inreducingtheincidenceoffebrileneutropenia (FN) inptswithlocally-advanced (LA) ormetastatic (m)CRC receivingfirst-linetreatmentwitheither FOLFOX/B or FOLFIRI/B. Methods: Keyeligibility: 18 yearsold; measurable, nonresectable CRC per RECIST 1.1. Ptswererandomlyassigned 1:1 toeitherplaceboor 6 mg PEG ~24 h afterctx/B. Thestudytreatmentperiodincludedfour Q2W cycles, butptscouldcontinuetheirassignedregimenuntilprogression. Ptswerestratifiedbyregion (NorthAmericavsrestofworld), stage (LA vsmCRC), andctx (FOLFOX vs FOLFIRI). Estimatedsamplesize (N = 800) wasbasedontheexpectedincidenceofgrade 3/4 FN (primaryendpoint) acrossthefirst 4 cyclesofctx/B, poweredfor PEG superiorityoverplacebo. Otherendpointsincludedoverallresponserate (ORR), progression-freesurvival (PFS), andoverallsurvival (OS). Results: 845 ptswererandomized (Nov 2009 toJan 2012) andreceivedstudytreatment; 783 ptscompleted 4 cyclesofctx/B. Medianagewas 61 years; 512 (61%) ptsweremale; 819 (97%) hadmCRC; 414 (49%) received FOLFOX, and 431 (51%) received FOLFIRI. Grade 3/4 FN (first 4 cycles) forplacebovs PEG was 5.7% vs 2.4%; OR 0.41; p = 0.014. A similarincidenceofother grade 3 adverseeventswasseeninbotharms (28% placebo; 27% PEG). Seetableforadditionalresults. Conclusions:PEGsignificantlyreducedtheincidenceofgrade 3/4 FN inthisptpopulationreceivingstandardctx/B for CRC. Follow-upisongoing. | uk |
dc.language.iso | en | uk |
dc.publisher | JournalofClinicalOncology, 2013 ASCO AnnualMeetingAbstracts. Vol 31, No 15_suppl (May 20 Supplement), 2013: 3575 | uk |
dc.title | Resultsof a phase III, randomized, double-blind, placebocontrolledtrialofpegfilgrastim (PEG) inpatients (pts) receivingfirst-line FOLFOX or FOLFIRI andbevacizumab (B) forcolorectalcancer (CRC) | uk |
dc.type | Text | uk |
dc.pubType | Стаття | uk |
Appears in Collections: | Наукові публікації кафедри радіології та онкології |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Journal_of_Clinical_Oncolog2.PDF | 91.53 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.